AbbVie To Present TURQUOISE-II Study Results At ILC

(RTTNews) - AbbVie (ABBV) announced detailed results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis from its hepatitis C development program would be presented today at the International Liver Congress or ILC 2014 and featured in the ILC press conference.

Data from a pivotal phase III study, TURQUOISE-II will be presented as a late-breaker. Additionally, results from the study have been published online in The New England Journal of Medicine.

TURQUOISE-II is a randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie's regimen with ribavirin in adult patients with genotype 1 chronic hepatitis C virus infection with compensated liver cirrhosis. Response rate of patients varied between 91.8 percent and 95.9 percent in the 12-week and 24-week treatment arms, respectively.

The company said that results from the TURQUOISE-II study demonstrate that high SVR12 rates can be achieved in GT1 patients with compensated liver cirrhosis in both 12-week and 24-week treatment durations.

On-treatment virologic failure occurred in one patient in the 12-week arm and three patients in the 24-week arm. In addition, 12 patients in the 12-week arm and one patient in the 24-week arm experienced relapse within 12 weeks post-treatment, the report stated.

Enanta Pharmaceuticals said in a statement that TURQUOISE-II study reports results from AbbVie's investigational three direct-acting antiviral regimen containing ABT-450, Enanta's lead protease inhibitor discovered through Enanta's collaboration with AbbVie. The regimen consists of boosted protease inhibitor ABT-450/ritonavir, NS5A inhibitor ABT-267, and non-nucleoside polymerase inhibitor ABT-333.